Literature DB >> 11427206

Fibromuscular cap composition is important for the stability of established atherosclerotic plaques in mature WHHL rabbits treated with statins.

M Shiomi1, T Ito, Y Hirouchi, M Enomoto.   

Abstract

We examined the relationship between plaque vulnerability and fibromuscular cap composition using hydrophilic pravastatin and lipophilic fluvastatin. WHHL rabbits aged 10 months were given pravastatin (50 mg/kg) or fluvastatin (20 mg/kg) for 52 weeks. The atherosclerotic lesions were immunohistochemically or conventionally stained and the components were analyzed with a color image analyzer. Compared with the control group, the plasma cholesterol levels were decreased by about 25% in both statin groups. Pravastatin decreased the lipid components (macrophages+extracellular lipids) in whole aortic plaques by 34% and the fibrous caps of coronary plaques by 55%. Fluvastatin decreased the fibromuscular components (smooth muscle cells+collagen fibers) in whole aortic plaques and in the fibromuscular caps of the aortic and coronary plaques. In the pravastatin group, the vulnerability index, the ratio of (lipid components)/(fibromuscular components), was decreased in whole aortic plaques by 28% and in the fibromuscular caps of coronary lesions by 61%, while the indexes were increased in the fluvastatin group. The incidence of vulnerable plaques was decreased by 74% in the coronary plaques of the pravastatin group. Our results suggest that the stability of atheromatous plaques was improved due to a decrease of the lipid components and vulnerability index of the fibromuscular cap by pravastatin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11427206     DOI: 10.1016/s0021-9150(00)00708-5

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  37 in total

Review 1.  Platelet-endothelial interactions in atherosclerosis.

Authors:  B S Sachais
Journal:  Curr Atheroscler Rep       Date:  2001-09       Impact factor: 5.113

Review 2.  Pathologic assessment of the vulnerable human coronary plaque.

Authors:  F D Kolodgie; R Virmani; A P Burke; A Farb; D K Weber; R Kutys; A V Finn; H K Gold
Journal:  Heart       Date:  2004-12       Impact factor: 5.994

3.  Radiolabelled probes for imaging of atherosclerotic plaques.

Authors:  Takashi Temma; Hideo Saji
Journal:  Am J Nucl Med Mol Imaging       Date:  2012-10-15

4.  Utility of contrast-enhanced ultrasonography for qualitative imaging of atherosclerosis in Watanabe heritable hyperlipidemic rabbits: initial experimental study.

Authors:  Ayumi Nitta-Seko; Norihisa Nitta; Masashi Shiomi; Akinaga Sonoda; Shinichi Ota; Keiko Tsuchiya; Masashi Takahashi; Mineko Fujimiya; Murata Kiyoshi
Journal:  Jpn J Radiol       Date:  2010-11-27       Impact factor: 2.374

5.  p-Cresyl sulfate promotes the formation of atherosclerotic lesions and induces plaque instability by targeting vascular smooth muscle cells.

Authors:  Hui Han; Yanjia Chen; Zhengbin Zhu; Xiuxiu Su; Jingwei Ni; Run Du; Ruiyan Zhang; Wei Jin
Journal:  Front Med       Date:  2016-09-07       Impact factor: 4.592

6.  Lapaquistat acetate, a squalene synthase inhibitor, changes macrophage/lipid-rich coronary plaques of hypercholesterolaemic rabbits into fibrous lesions.

Authors:  M Shiomi; S Yamada; Y Amano; T Nishimoto; T Ito
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

7.  GDF11 Protects against Endothelial Injury and Reduces Atherosclerotic Lesion Formation in Apolipoprotein E-Null Mice.

Authors:  Wen Mei; Guangda Xiang; Yixiang Li; Huan Li; Lingwei Xiang; Junyan Lu; Lin Xiang; Jing Dong; Min Liu
Journal:  Mol Ther       Date:  2016-08-09       Impact factor: 11.454

Review 8.  Plaque Rupture and Thrombosis: the Value of the Atherosclerotic Rabbit Model in Defining the Mechanism.

Authors:  Oliver G Abela; Chowdhury H Ahsan; Fadi Alreefi; Negar Salehi; Imran Baig; Abed Janoudi; George S Abela
Journal:  Curr Atheroscler Rep       Date:  2016-06       Impact factor: 5.113

9.  Beneficial effects of fluvastatin following percutaneous coronary intervention in patients with unstable and stable angina: results from the Lescol intervention prevention study (LIPS).

Authors:  C H Lee; P de Feyter; P W Serruys; F Saia; P A Lemos; D Goedhart; P R Soares; V A W M Umans; M Ciccone; M Cortellaro
Journal:  Heart       Date:  2004-10       Impact factor: 5.994

10.  Suppression of coronary atherosclerosis by helix B surface Peptide, a nonerythropoietic, tissue-protective compound derived from erythropoietin.

Authors:  Hiroto Ueba; Masashi Shiomi; Michael Brines; Michael Yamin; Tsutomu Kobayashi; Junya Ako; Shin-Ichi Momomura; Anthony Cerami; Masanobu Kawakami
Journal:  Mol Med       Date:  2013-07-24       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.